EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Consensus molecular subtype transition during progression of colorectal cancer

Simone van de Weerd iD, Arezo Torang, Liselotte W Zwager, Pim J Koelink, Jan Koster, Barbara Aj Bastiaansen, Veerle Lammers, Ciro Longobardi, Jeanine Ml Roodhart, J Han van Krieken, Arantza Farina Sarasqueta, Evelien Dekker und 1 weitere

The Journal of Pathology · 2023-11 · 261 (3) · 298-308

DOI: 10.1002/path.6176 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Pathology, online erschienen am 08.09.2023. Verfasst von Simone van de Weerd und 12 weiteren Autor:innen. Beteiligte Einrichtung: Amsterdam UMC, University of Amsterdam, Center for Experimental and Molecular Medicine, Cancer Center Amsterdam, Amsterdam, The Netherlands. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Biomarkers, Tumor, Adenoma, Cell Transformation, Neoplastic. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: KWF Kankerbestrijding, Oncode Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The consensus molecular subtype (CMS) classification divides colorectal cancer (CRC) into four distinct subtypes based on RNA expression profiles. The biological differences between CMSs are already present in CRC precursor lesions, but not all CMSs pose the same risk of malignant transformation. To fully understand the path to malignant transformation and to determine whether CMS is a fixed entity during progression, genomic and transcriptomic data from two regions of the same CRC lesion were compared: the precursor region and the carcinoma region. In total, 24 patients who underwent endoscopic removal of T1–2 CRC were included. Regions were subtyped for CMS and DNA mutation analysis was performed. Additionally, a set of 85 benign adenomas was CMS‐subtyped. This analysis revealed that almost all benign adenomas were classified as CMS3 (91.8%). In contrast, CMS2 was the most prevalent subtype in precursor regions (66.7%), followed by CMS3 (29.2%). CMS4 was absent in precursor lesions and originated at the carcinoma stage. Importantly, CMS switching occurred in a substantial number of cases and almost all (six out of seven) CMS3 precursor regions showed a shift to a different subtype in the carcinoma part of the lesion, which in four cases was classified as CMS4. In conclusion, our data indicate that CMS3 is related to a more indolent type of precursor lesion that less likely progresses to CRC and when this occurs, it is often associated with a subtype change that includes the more aggressive mesenchymal CMS4. In contrast, an acquired CMS2 signature appeared to be rather fixed during early CRC development. Combined, our data show that subtype changes occur during progression and that CMS3 switching is related to changes in the genomic background through acquisition of a novel driver mutation ( TP53 ) or selective expansion of a clone, but also occurred independently of such genetic changes. © 2023 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsBiomarkers, TumorAdenomaCell Transformation, NeoplasticHumansDisease ProgressionMaleFemaleAgedMiddle AgedMutationDNA Mutational AnalysisGene Expression ProfilingAged, 80 and overConsensusTranscriptome

Stichwörter der Autor:innen

adenomacolorectal cancerconsensus molecular subtypesgene expression profilingmolecular stratificationmutational profiling

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Amsterdam UMC, University of Amsterdam, Center for Experimental and Molecular Medicine, Cancer Center Amsterdam, Amsterdam, The Netherlands.
  • Department of Pathology, Radboud University Medical Centre, Nijmegen, The Netherlands.
  • Oncode Institute, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
  • Department of Gastroenterology and Hepatology, Amsterdam UMC, location AMC, Cancer Center Amsterdam and Amsterdam Gastroenterology & Metabolism, University of Amsterdam, Amsterdam, The Netherlands.
  • Tytgat Institute for Liver and Intestinal Research, Amsterdam Gastroenterology and Metabolism, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
  • Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.

ORCID-Profile: Simone van de Weerd

Förderung

  • KWF Kankerbestrijding
  • Oncode Institute

Zitieren

APA

van de Weerd, S., Torang, A., Zwager, L. W., Koelink, P. J., Koster, J., Bastiaansen, B. A., Lammers, V., Longobardi, C., Roodhart, J. M., van Krieken, J. H., Farina Sarasqueta, A., Dekker, E., & Medema, J. P. (2023). Consensus molecular subtype transition during progression of colorectal cancer. The Journal of Pathology, 261(3), 298-308. https://doi.org/10.1002/path.6176

Vancouver

van de Weerd S, Torang A, Zwager LW, Koelink PJ, Koster J, Bastiaansen BA, et al. Consensus molecular subtype transition during progression of colorectal cancer. The Journal of Pathology. 2023;261(3):298-308. doi:10.1002/path.6176

BibTeX
@article{vandeWeerd2023,
  author = {van de Weerd, Simone and Torang, Arezo and Zwager, Liselotte W and Koelink, Pim J and Koster, Jan and Bastiaansen, Barbara Aj and Lammers, Veerle and Longobardi, Ciro and Roodhart, Jeanine Ml and van Krieken, J Han and Farina Sarasqueta, Arantza and Dekker, Evelien and Medema, Jan Paul},
  title = {Consensus molecular subtype transition during progression of colorectal cancer},
  journal = {The Journal of Pathology},
  year = {2023},
  volume = {261},
  number = {3},
  pages = {298--308},
  doi = {10.1002/path.6176}
}
Kostenlos starten →